Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02560324 · ClinicalTrials.gov registry record · Phase 2
Effect of Ramelteon on Smoking Abstinence
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT02560324: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT02560324 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02560324, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled crossover study to test whether a medication called ramelteon (Brand Name: Remeron) will help smokers quit and whether it reduces sleep problems that smokers experience during a quit attempt.
Interventions
- DRUG Placebo
- DRUG Ramelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02560324
The ClinicalTrials.gov registry entry for NCT02560324 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02560324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02560324 about?
NCT02560324 is a clinical study titled "Effect of Ramelteon on Smoking Abstinence". This is a randomized, double-blind, placebo-controlled crossover study to test whether a medication called ramelteon (Brand Name: Remeron) will help smokers quit and whether it reduces sleep problems that smokers experience during a quit attempt.
What is the current status of trial NCT02560324?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2015-09. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02560324?
The interventions under investigation include: Placebo (DRUG), Ramelteon (DRUG).
Who is sponsoring clinical trial NCT02560324?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.